Monte Rosa Therapeutics, Inc. [GLUE]

Source: 

Company Overview

We are a biopharmaceutical company developing a portfolio of novel and proprietary small molecule drugs that employ the bodys natural mechanisms to selectively degrade therapeutically-relevant proteins, so called molecular glue degraders or MGDs. We have developed a proprietary protein degradation platform, called QuEEN (an abbreviation for Quantitative and Engineered Elimination of Neosubstrates), to enable our target-centric approach to our MGD discovery and development.